Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

GLAUKOS CORP.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1998-01-01

Employees: 907

Market Cap: $7.4B

Website: http://www.glaukos.com

Clinical Trials

A Prospective Evaluation of Glaucoma Subjects Treated With Two Second Generation iStents and One iStent Supra

Not Applicable

Terminated

Conditions: Glaucoma, Open-Angle

Interventions: Device: G2 and G3

First Posted Date: 2017-08-21

Last Posted Date: 2022-09-09

Lead Sponsor: Glaukos Corporation

Target Recruit Count: 7

Registration Number: NCT03255798

Locations: 🇩🇪
Prof. Dr. med. Carl Erb, Berlin, Germany

Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents

Phase 4

Completed

Conditions: Open-angle Glaucoma

Interventions: Procedure: Implantation of two iStent inject micro-bypass stents
Drug: Topical travoprost
Device: Two iStent inject micro-bypass stents
Drug: Tobramycin
Drug: Dexamethasone

First Posted Date: 2016-08-22

Last Posted Date: 2022-09-07

Lead Sponsor: Glaukos Corporation

Target Recruit Count: 53

Registration Number: NCT02873806

Locations: 🇦🇲
S.V. Malayan's Ophtalmology Centre, Yerevan, Armenia

Two Second-Generation Trabecular Micro-bypass Stents to Treat Glaucoma Subjects on One Hypotensive Medication

Phase 4

Completed

Conditions: Open Angle Glaucoma

Interventions: Device: Two trabecular micro-bypass stents (iStent inject)

First Posted Date: 2016-08-16

Last Posted Date: 2022-09-08

Lead Sponsor: Glaukos Corporation

Target Recruit Count: 57

Registration Number: NCT02868190

Locations: 🇦🇲
S.V. Malayan's Ophtalmology Centre, Yerevan, Armenia

Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution

Phase 2

Completed

Conditions: Glaucoma Open-angle

Interventions: Drug: Travoprost Intraocular Implant, low elution
Drug: Travoprost Intraocular Implant, high elution
Drug: Timolol Maleate Ophthalmic Solution, 0.5%

First Posted Date: 2016-04-28

Last Posted Date: 2023-09-26

Lead Sponsor: Glaukos Corporation

Target Recruit Count: 154

Registration Number: NCT02754596

Locations: 🇺🇸
John Berdahl, MD, Sioux Falls, South Dakota, United States

Multicenter Investigation of Trabecular Micro-Bypass Stents vs. Laser Trabeculoplasty

Not Applicable

Terminated

Conditions: Primary Open-Angle Glaucoma

Interventions: Procedure: Laser
Device: Stents
Device: Laser Trabeculoplasty

First Posted Date: 2014-12-30

Last Posted Date: 2022-12-22

Lead Sponsor: Glaukos Corporation

Target Recruit Count: 91

Registration Number: NCT02327312

Safety and Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus

Phase 3

Terminated

Conditions: Keratoconus

Interventions: Drug: placebo solution
Drug: riboflavin solution
Device: KXL System

First Posted Date: 2013-10-31

Last Posted Date: 2021-04-26

Lead Sponsor: Glaukos Corporation

Target Recruit Count: 92

Registration Number: NCT01972854

Locations: 🇺🇸
UC Irvine Department of Ophthalmology, Irvine, California, United States
🇺🇸
Gordon -Weiss Vision Institute, San Diego, California, United States
🇺🇸
Price Vision Group, Indianapolis, Indiana, United States

and more 8 locations

Safety and Efficacy of Corneal Collagen Cross-linking Following LASIK for Treatment of Hyperopia and Hyperopic Astigmatism

Phase 1

Terminated

Conditions: Hyperopia
Hyperopic Astigmatism

Interventions: Drug: riboflavin ophthalmic solution, 0% dextran
Device: UVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA)
Device: UVA Irradiation (30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off)
Procedure: Laser-assisted in situ keratomileusis

First Posted Date: 2013-07-09

Last Posted Date: 2021-04-26

Lead Sponsor: Glaukos Corporation

Target Recruit Count: 2

Registration Number: NCT01893359

Locations: 🇺🇸
Gordon -Weiss-Schanzlin Vision Institute, San Diego, California, United States
🇺🇸
Ophthalmic Consultants of Boston, Waltham, Massachusetts, United States
🇺🇸
Hersh Vision Group, Teaneck, New Jersey, United States

and more 2 locations

Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry

Completed

Conditions: Primary Open-angle Glaucoma

Interventions: Device: iStent

First Posted Date: 2013-04-26

Last Posted Date: 2017-12-18

Lead Sponsor: Glaukos Corporation

Target Recruit Count: 191

Registration Number: NCT01841437

Multicenter Post-Approval Study Of The Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery

Not Applicable

Conditions: Primary Open Angle Glaucoma

Interventions: Device: iStent
Procedure: Cataract surgery

First Posted Date: 2013-04-26

Last Posted Date: 2021-10-20

Lead Sponsor: Glaukos Corporation

Target Recruit Count: 360

Registration Number: NCT01841450

Post-approval Study of The Glaukos® iStent® Trabecular Micro-bypass Stent: Extended Follow-up of the Premarket Cohort

Completed

Conditions: Primary Open Angle Glaucoma

First Posted Date: 2013-04-19

Last Posted Date: 2016-04-15

Lead Sponsor: Glaukos Corporation

Target Recruit Count: 108

Registration Number: NCT01836042

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy